ADial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Co.'s investigational new drug product, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. Co. has a license from the University of Virginia Patent Foundation to commercialize its AD04. The active pharmaceutical agent in AD04, Co.'s investigational new drug product, is ondansetron, which is also the active ingredient in Zofran®, an approval for nausea and vomiting post-operatively and after chemotherapy or radiation treatment and is commercially available in generic form. The ADIL average annual return since 2018 is shown above.
The Average Annual Return on the ADIL average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ADIL average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ADIL average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|